利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.011 秒)

    Fc fusion proteins of human growth hormone
    1.
    发明授权
    Fc fusion proteins of human growth hormone 有权
    人类生长激素的Fc融合蛋白

    公开(公告)号：US08637637B2

    公开(公告)日：2014-01-28

    申请号：US12657004

    申请日：2010-01-12

    申请人： Bill Nai-Chau Sun ,  Ruey-shyan Liou ,  Cecily Rou-Yun Sun ,  Lee-Hwei King Sun

    发明人： Bill Nai-Chau Sun ,  Ruey-shyan Liou ,  Cecily Rou-Yun Sun ,  Lee-Hwei King Sun

    IPC分类号： C07K17/00

    CPC分类号： C07K14/61 ,  C07K2319/30

    摘要： Fc fusion proteins of human growth hormone with good biological activities relative to rhGH on a molar basis are disclosed. The hGH-L-vFc fusion protein comprises hGH, a flexible peptide linker of about 20 or fewer amino acids, and a human IgG Fc variant. The Fc variant is of a non-lytic nature and shows minimal undesirable Fc-mediated side effects. A method is also disclosed to make or produce such fusion proteins at high expression levels. Such hGH-L-vFc fusion proteins exhibit extended or prolonged serum half-life and/or good biological activities relative to that of rhGH on a molar basis, leading to improved pharmacokinetics and pharmacodynamics, thus fewer injections will be needed within a period of time.

    摘要翻译： 公开了以摩尔计相对于rhGH的具有良好生物活性的人生长激素的Fc融合蛋白。 hGH-L-vFc融合蛋白包含hGH，约20个或更少氨基酸的柔性肽接头和人IgG Fc变体。 Fc变体具有非溶解性质并且显示出最小的不期望的Fc介导的副作用。 还公开了以高表达水平制备或产生这种融合蛋白的方法。 这样的hGH-L-vFc融合蛋白在摩尔基础上相对于rhGH显示出延长的或延长的血清半衰期和/或良好的生物活性，导致改善的药代动力学和药效学，因此在一段时间内将需要更少的注射 。

    Fc fusion proteins of human growth hormone
    4.
    发明申请
    Fc fusion proteins of human growth hormone 有权
    人类生长激素的Fc融合蛋白

    公开(公告)号：US20120116056A1

    公开(公告)日：2012-05-10

    申请号：US12657004

    申请日：2010-01-12

    申请人： Bill Nai-Chau Sun ,  Ruey-shyan Liou ,  Cecily Rou-Yun Sun ,  Lee-Hwei King Sun

    发明人： Bill Nai-Chau Sun ,  Ruey-shyan Liou ,  Cecily Rou-Yun Sun ,  Lee-Hwei King Sun

    IPC分类号： C07K19/00 ,  C12P21/02 ,  C12N5/10

    CPC分类号： C07K14/61 ,  C07K2319/30

    摘要： Fc fusion proteins of human growth hormone with good biological activities relative to rhGH on a molar basis are disclosed. The hGH-L-vFc fusion protein comprises hGH, a flexible peptide linker of about 20 or fewer amino acids, and a human IgG Fc variant. The Fc variant is of a non-lytic nature and shows minimal undesirable Fc-mediated side effects. A method is also disclosed to make or produce such fusion proteins at high expression levels. Such hGH-L-vFc fusion proteins exhibit extended or prolonged serum half-life and/or good biological activities relative to that of rhGH on a molar basis, leading to improved pharmacokinetics and pharmacodynamics, thus fewer injections will be needed within a period of time.

    摘要翻译： 公开了以摩尔计相对于rhGH的具有良好生物活性的人生长激素的Fc融合蛋白。 hGH-L-vFc融合蛋白包含hGH，约20个或更少氨基酸的柔性肽接头和人IgG Fc变体。 Fc变体具有非溶解性质并且显示出最小的不期望的Fc介导的副作用。 还公开了以高表达水平制备或产生这种融合蛋白的方法。 这样的hGH-L-vFc融合蛋白在摩尔基础上相对于rhGH显示出延长的或延长的血清半衰期和/或良好的生物活性，导致改善的药代动力学和药效学，因此在一段时间内将需要更少的注射 。